A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Naval DaverMarina Konopleva

Abstract

Previous studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies. This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL). Twenty-four patients were treated; 15 received everolimus 5 mg/day and 9 received 10 mg/day with HyperCVAD. The median age of patients was 25 years (range, 11-64) and median number of prior treatments was 2 (range, 1-7). Grade 3 mucositis was the dose-limiting toxicity and the maximum tolerated everolimus dose was 5 mg/day. Responses included complete remission (CR) in 6 patients (25%), CR without platelet recovery (CRp) in 1 (4%), and CR without recovery of counts (CRi) in 1 (4%), for an overall response rate of 33%. In addition, partial response (PR) was noted in 2 patients (8%). Seven of 11 patients treated in first salvage achieved CR/CRp (64%). The median OS was 29 weeks for patients in first salvage versus 15 weeks for patients in second salvage and beyond (P ≤ 0.001). A response was noted in 5 of 10 (50%) heavily pretreated T-ALL patients (median of 4 prior salvage regimens). Everolimus significantly inhibited ...Continue Reading

References

Jan 1, 1996·Annual Review of Immunology·R T Abraham, G J Wiederrecht
Feb 2, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianE J Freireich
Nov 1, 2000·Cell·T Schmelzle, M N Hall
Apr 12, 2001·Genes & Development·A C GingrasN Sonenberg
Aug 16, 2001·Proceedings of the National Academy of Sciences of the United States of America·M S NeshatC L Sawyers
Aug 2, 2002·Cancer Cell·Shivapriya RamaswamyWilliam R Sellers
Sep 21, 2002·Molecular and Cellular Biology·Christine C HudsonRobert T Abraham
Oct 11, 2002·Advances in Cancer Research·Kathleen A Martin, John Blenis
Dec 6, 2003·Proceedings of the National Academy of Sciences of the United States of America·Valerie I BrownStephan A Grupp
Jan 30, 2004·Clinical Pharmacokinetics·Gabriele I KirchnerMichael P Manns
May 10, 2005·Blood·Raffaella AvellinoMaria Fiammetta Romano
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
May 3, 2006·The Laryngoscope·Samir S KhariwalaMarshall Strome
Sep 5, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karen W L YeeFrancis J Giles
Jul 7, 2007·Cancer Cell·David A Guertin, David M Sabatini
Jul 31, 2007·Critical Reviews in Oncology/hematology·Kathrin T DoepfnerAlexandre Arcaro
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Josep TaberneroJosé Baselga
Mar 12, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anne O'DonnellIan Judson
Oct 11, 2008·Cancer·Susan O'BrienHagop M Kantarjian
Oct 29, 2008·Proceedings of the National Academy of Sciences of the United States of America·Andrew Y ChooJohn Blenis
Apr 5, 2013·Immunological Reviews·Esmerina TiliCarlo M Croce
Apr 5, 2013·Cancer Science·Hiroyuki TagawaKenichi Sawada

❮ Previous
Next ❯

Citations

Jun 4, 2016·Blood·David A Fruman
Jan 26, 2016·British Journal of Clinical Pharmacology·Jong-Hoon Scott LeeDavid A Fruman
Feb 2, 2017·British Journal of Haematology·Teresa Calimeri, Andrés J M Ferreri
Mar 30, 2017·Current Hematologic Malignancy Reports·Louise M ManMichael Keng
Jun 14, 2017·Expert Opinion on Pharmacotherapy·Raoul SantiagoHenrique Bittencourt
Sep 22, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Renato BassanSabina Chiaretti
Dec 11, 2019·Cells·Cedric MagawayEstela Jacinto
Jun 29, 2018·International Journal of Molecular Sciences·Camilla EvangelistiAlberto M Martelli
Feb 24, 2019·Cells·Carolina SimioniLuca M Neri
Mar 19, 2020·Frontiers in Oncology·Bruno FattizzoNicola Stefano Fracchiolla
Feb 14, 2017·Biomarker Research·Tasleem Katchi, Delong Liu
Oct 2, 2019·Cancers·Francesca CuomoGilda Cobellis
Jun 2, 2017·Molecular Cancer Therapeutics·Thanh-Trang T VoDavid A Fruman
Jan 26, 2021·Frontiers in Oncology·Yimei FengXi Zhang
May 1, 2021·International Journal of Molecular Sciences·Marta Weronika LatoMonika Lejman
May 5, 2021·British Journal of Haematology·Rachael PocockMarc R Mansour
Jul 3, 2021·International Journal of Molecular Sciences·Vincent KuekLaurence C Cheung
Jun 24, 2019·Pathology, Research and Practice·Xi ChenYinghua Li

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.